For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Veeva Systems Inc.VEEV US · Health Care · USD Current price$277.20as of Nov 19, 2026 Summary
Analyst consensusStrong Buy 7Buy 13Hold 8Sell 127 analysts 3-year price (USD)Factor profileMulti-factor score 82 / 100 Market data
Business descriptionVeeva Systems Inc. is the dominant cloud-based software provider for the global life sciences industry. Operating with an 84% subscription revenue mix, Veeva provides mission-critical Commercial Cloud solutions (Vault CRM, Veeva Link, Compass) and Development Cloud suites spanning clinical trials, regulatory compliance, and safety functions for top-20 biopharma enterprises (including Eli Lilly and Amgen) and thousands of mid-size biotech firms. Strategic Position & Moat
Recent Developments & Earnings Context
Key Catalysts
Risks & Monitoring
Financials
Classification
|
Last updated: Sep 21, 2026
Current price: $277.20 · Nov 19, 2026· USD
CFRA Ratingstrong buy
TBI Multi Score82
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: VEEVBusiness description
Veeva Systems Inc. is the dominant cloud-based software provider for the global life sciences industry. Operating with an 84% subscription revenue mix, Veeva provides mission-critical Commercial Cloud solutions (Vault CRM, Veeva Link, Compass) and Development Cloud suites spanning clinical trials, regulatory compliance, and safety functions for top-20 biopharma enterprises (including Eli Lilly and Amgen) and thousands of mid-size biotech firms.
Strategic Position & Moat
- High Switching Costs & Regulatory Integration: Deeply embedded across regulatory workflows (FDA/EMA submissions) and field commercial operations, creating high customer stickiness and multi-year contract retention.
- Top-20 Biopharma Vault CRM Migration: Signed 13 of the top-20 global biopharma companies onto the Vault CRM platform as of Q2 FY27 (notably Eli Lilly in August 2026 and Amgen in September 2026), with over 180 customers live globally.
- Agentic AI Expansion (Veeva Falcon): Launched "Veeva AI Agents" for CRM and "Veeva Falcon" — an agentic AI platform for clinical, regulatory, and safety operations — with five early adopters in Q2 FY27. Bolstered conversational AI capabilities via the $100M acquisition of Ostro in March 2026.
- Financial Fortitude & Capital Return: Operates with zero net debt (~$7.2B in cash and short-term investments as of July 2026) and a $2B share buyback authorization ($473M repurchased in 1H FY27). Target revenue run rate set at $6B by 2030 (crossed $3B in FY26).
Recent Developments & Earnings Context
- Q2 FY27 Milestone Announcements: Announced global Vault CRM adoption by Amgen (bringing top-20 biopharma commitments to 13) and full U.S. field deployment of Vault CRM with the Agentic Call Report by a top-20 firm.
- CFRA Focus Stock Upgrade (09/21/2026): Carries CFRA's highest recommendation of Strong Buy (5-STARS) with a 12-Month Target Price of USD 330.00 (reflecting 35.7x FY27E Oper. EPS). Close price USD 260.21 (09/18/2026).
- Earnings Guidance: Oper. EPS estimates at USD 9.24 for FY27E and USD 10.25 for FY28E.
Key Catalysts
- Full commercial rollout and initial go-lives of the Veeva Falcon agentic platform across clinical/regulatory workflows through 1H 2027.
- Acceleration in Vault CRM migrations as legacy Salesforce-partnered CRM contracts expire.
- Expansion of newer Data Cloud products (Veeva Link real-time data, Compass prescriber/patient data) across non-life sciences verticals (consumer products, specialty chemicals).
Risks & Monitoring
- Salesforce Relationship Transition: Operational execution risks as customers transition away from legacy Salesforce infrastructure to native Vault CRM.
- Biotech Capex & Funding Sensitivities: Budget constraints or trial delays among emerging small/mid-cap biotech customers in a sustained high interest rate environment.
Market Data
Source: mkts.io · Nov 19, 2026, 00:00 UTC
Key Metrics
P/E (TTM)45.44
P/E (Fwd)27.01
Dividend0.00%
Beta0.88
52W High$325.99
52W Low$148.05
Analyst Consensus
7
13
8
Strong Buy7Buy13Hold8Sell127 analysts
Consensus Target$326.41
+17.8% upside
Calendar Events
Next EarningsDec 3, 2026
Financials
Revenue$3.46B
Rev Growth17.60%
Earnings Growth39.50%
Gross Margin74.96%
Op Margin29.93%
Profit Margin29.34%
EBITDA$1.08B
ROA7.58%
ROE14.42%
Rev/Share$21.15
Total Cash$7.24B
Total Debt$151.70M
D/E Ratio2.04
Free Cash Flow$1.26B
Op Cash Flow$1.67B
Current Ratio5.46
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 2.34 | $935.18M |
| +1q | 2.31 | $944.13M |
| 0y | 9.24 | $3.69B |
| +1y | 10.26 | $4.15B |
Earnings
Quarterly EPS
3Q2025
Est: 1.952.04Beat
4Q2025
Est: 1.942.06Beat
1Q2026
Est: 2.142.24Beat
2Q2026
Est: 2.222.35Beat
Annual
2023
Rev $2.16BEarn $487.71M
2024
Rev $2.36BEarn $525.71M
2025
Rev $2.75BEarn $714.14M
2026
Rev $3.20BEarn $908.91M
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 11, 2026 | Wells Fargo | main | Overweight |
| Nov 9, 2026 | Canaccord Genuity | main | Hold |
| Nov 9, 2026 | Truist Securities | main | Buy |
| Nov 9, 2026 | BTIG | main | Buy |
| Nov 7, 2026 | Jefferies | main | Buy |
| Nov 6, 2026 | UBS | main | Neutral |
